Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha
SA Heart Journal, 2017 Introduction: Fenofibrate exerts pleiotropic effects on endothelial cells (ECs) by, amongst others, increasing nitric oxide (NO) production. We aimed to investigate fenofi brate’s putative beneficial actions in healthy or TNF-alpha-induced dysfunctional ...
Westcott, Corli +6 more
doaj +1 more source
EFFECT OF MILLING PROCESS ON PHYSICAL CHARACTERISTICS OF FENOFIBRATE [PDF]
, 2017 Particle size is ones of the most important characteristic of active drug substance that affects solubility and bioavailability. Fenofibrate, as a class II drug based on biopharmaceutical classification system, which has poor aqueous solubility has been ...
Avanti, Christina +2 more
core
Fenofibrate Inhibited the Differentiation of T Helper 17 Cells In Vitro
PPAR Research, 2012 Uncontrolled activity of T cells mediates autoimmune and inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, type 1 diabetes, and atherosclerosis.
Zhou Zhou +7 more
doaj +1 more source
Medication decision-making for patients with renal insufficiency in inpatient and outpatient care at a US Veterans Affairs Medical Centre: a qualitative, cognitive task analysis. [PDF]
, 2019 BackgroundMany studies identify factors that contribute to renal prescribing errors, but few examine how healthcare professionals (HCPs) detect and recover from an error or potential patient safety concern.
Arthur, Karen J +8 more
core +1 more source
Acta Pharmaceutica Sinica BFenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely prescribed for hyperlipidemia management. Recent studies also showed that it has therapeutic potential in various liver diseases.
Shicheng Fan +11 more
doaj +1 more source
PPAR-α and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal [PDF]
, 2014 Many acute and chronic anaemias, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond–Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit erythroid progenitors (CFU-Es) that ...
A Bauer +35 more
core +1 more source
Preparation And Evaluation Of Fenofibrate-Gelucire 44/14 Solid Dispersions [PDF]
, 2007 Potensi formulasi berasaskan sebaran pepejal menggunapakai Gelucire 44/14 sebagai pembawa untuk meningkatkan pelarutan serta biokeperolehan oral fenofibrat, sejenis drug yang tak mudah larut, telah disiasat.
Al-Dhalli, Samer
core +1 more source
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics [PDF]
, 2016 Drug-drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea use with a statin or fibrate was associated with severe hypoglycemia. We conducted cohort studies
Bilker, Warren B. +8 more
core +1 more source
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]
Journal of Lipid Research, 2010 Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals.
Mary K. Wojczynski +8 more
doaj +1 more source
Recent advances in the engineering of nanosized active pharmaceutical ingredients: Promises and challenges [PDF]
, 2016 The advances in the field of nanotechnology have revolutionized the field of delivery of poorly soluble active pharmaceutical ingredients (APIs). Nanosized formulations have been extensively investigated to achieve a rapid dissolution and therefore ...
Al Shafiee, Maen, Kaialy, Waseem
core +1 more source